Cargando…

Optimum fractionation of radiation to combine PD‐1 blockade

The optimum fractionation of radiation to combine with immune checkpoint blockade is controversial. This study aimed to investigate the fractionated radiation to maximize immunity during combination therapy. To evaluate the abscopal effect, C57BL/6 hPD‐1 knock‐in mice bearing two syngeneic contralat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, Feifei, Yin, Tianwen, Ju, Xiao, Wang, Peiliang, Wang, Yungang, Yu, Jinming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188465/ https://www.ncbi.nlm.nih.gov/pubmed/37206639 http://dx.doi.org/10.1002/mco2.271

Ejemplares similares

Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
por: Teng, Feifei, et al.
Publicado: (2020)

Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study
por: Wang, Peiliang, et al.
Publicado: (2021)

Prediction of the effects of radiation therapy in esophageal cancer using diffusion and perfusion MRI
por: Wang, Peiliang, et al.
Publicado: (2021)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature
por: Chen, Yu, et al.
Publicado: (2020)

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
por: Gong, Jun, et al.
Publicado: (2018)

The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?
por: Yin, Tianwen, et al.
Publicado: (2021)

PD-L1 expression in human cancers and its association with clinical outcomes
por: Wang, Xin, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Research on the optimum carbonization process of walnut shell based on dynamic analysis
por: Liu, Yang, et al.
Publicado: (2023)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
por: Yi, Ming, et al.
Publicado: (2022)

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
por: Razaghi, Ali, et al.
Publicado: (2023)

Optimum radiation source for radiation therapy of skin cancer
por: Safigholi, Habib, et al.
Publicado: (2015)

A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen
por: Yin, Jun, et al.
Publicado: (2022)

High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Neuroinflammatory changes of the normal brain tissue in cured mice following combined radiation and anti-PD-1 blockade therapy for glioma
por: Clausi, Mariano Guardia, et al.
Publicado: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy
por: Wang, Xin, et al.
Publicado: (2020)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
por: Page, David B., et al.
Publicado: (2019)

A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
por: Wang, Jing-Jing, et al.
Publicado: (2021)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
por: Burrack, Adam L., et al.
Publicado: (2019)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
por: Sun, Jin-Yu, et al.
Publicado: (2020)

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
por: Ge, Yanjun, et al.
Publicado: (2022)

PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer
por: Tuyaerts, Sandra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e2hqq8njc43pnmqapantekt2s8